These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 23807351)
1. A study of the association between patterns of eye drop prescription and medication usage in glaucoma subjects. Kawai-Tsuboi N; Kawai M; Minami Y; Yoshida A J Glaucoma; 2015 Mar; 24(3):202-6. PubMed ID: 23807351 [TBL] [Abstract][Full Text] [Related]
2. Evaluating eye drop instillation technique in glaucoma patients. Gupta R; Patil B; Shah BM; Bali SJ; Mishra SK; Dada T J Glaucoma; 2012 Mar; 21(3):189-92. PubMed ID: 21336146 [TBL] [Abstract][Full Text] [Related]
3. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients. O'Hare F; Jeganathan VS; Rokahr CG; Rogers SL; Crowston JG Clin Exp Ophthalmol; 2009 Dec; 37(9):849-54. PubMed ID: 20092593 [TBL] [Abstract][Full Text] [Related]
4. Efficiency of instillation methods for prostaglandin medications. Fiscella R; Wilensky JT; Chiang TH; Walt JG J Ocul Pharmacol Ther; 2006 Dec; 22(6):477-82. PubMed ID: 17238816 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication. Salyani A; Birt C Can J Ophthalmol; 2005 Apr; 40(2):170-4. PubMed ID: 16049530 [TBL] [Abstract][Full Text] [Related]
8. Topical prostaglandin fixed combinations in UK primary care: observational study using data from the health improvement network. Loftus J; Christopoulou D; Blak BT; Hards M Eur J Ophthalmol; 2012; 22(3):376-87. PubMed ID: 22034021 [TBL] [Abstract][Full Text] [Related]
9. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591 [TBL] [Abstract][Full Text] [Related]
11. Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Chang DS; Friedman DS; Frazier T; Plyler R; Boland MV Ophthalmology; 2013 Jul; 120(7):1396-402. PubMed ID: 23541760 [TBL] [Abstract][Full Text] [Related]
12. Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing. Ford BA; Gooi M; Carlsson A; Crichton AC J Glaucoma; 2013 Jan; 22(1):1-4. PubMed ID: 21946541 [TBL] [Abstract][Full Text] [Related]
13. The Relationship of Self-Report and Medication Possession With Glaucoma Medication Administration Success. Hein AM; Rosdahl JA; Bosworth HB; Woolson SL; Olsen MK; Kirshner MA; Muir KW J Glaucoma; 2019 Mar; 28(3):e46-e48. PubMed ID: 30822299 [TBL] [Abstract][Full Text] [Related]
14. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191 [TBL] [Abstract][Full Text] [Related]
15. Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study. Boland MV; Chang DS; Frazier T; Plyler R; Friedman DS JAMA Ophthalmol; 2014 Jul; 132(7):838-44. PubMed ID: 24830878 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Eye Drop Instillation Before and After Use of Drop Application Strips in Glaucoma Patients on Chronic Topical Therapy. Sharma R; Singhal D; Shashni A; Agarwal E; Wadhwani M; Dada T J Glaucoma; 2016 Apr; 25(4):e438-40. PubMed ID: 26550965 [TBL] [Abstract][Full Text] [Related]
17. Factors Affecting Adherence to Topical Glaucoma Therapy: A Quantitative and Qualitative Pilot Study Analysis in Sydney, Australia. Spencer SKR; Shulruf B; McPherson ZE; Zhang H; Lee MB; Francis IC; Bank A; Coroneo MT; Agar A Ophthalmol Glaucoma; 2019; 2(2):86-93. PubMed ID: 32672609 [TBL] [Abstract][Full Text] [Related]
18. Intraocular pressure control among patients transitioned from latanoprost to travoprost at a Veterans Affairs Medical Center Eye Clinic. McKinley SH; Singh R; Chang PT; Gross RL; Orengo-Nania S J Ocul Pharmacol Ther; 2009 Apr; 25(2):153-7. PubMed ID: 19284329 [TBL] [Abstract][Full Text] [Related]
19. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589 [TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination. Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]